#149 - AMA #20: Simplifying the complexities of insulin resistance: how it's measured, how it manifests in the muscle and liver, and what we can do about it

Episode Summary

Executive Summary: This AMA revisits Peter Atiyah’s prior conversation with Gerald Shulman on insulin resistance, aiming to simplify a dense but crucial topic. The episode explains insulin’s normal anabolic roles, how insulin resistance is defined and measured, why muscle and liver resistance matter, and why early detection via oral glucose tolerance testing is more useful clinically than fasting labs alone. The core message: insulin resistance is widespread, often silent, and central to metabolic disease risk.

Main Topics: Why revisit the Gerald Shulman episode (Priority: 5/5): The hosts explain that the original insulin resistance discussion was highly informative but technically dense, so this AMA slows it down and reconstructs the key ideas in a more digestible way. Normal insulin physiology (Priority: 5/5): Insulin is described as an anabolic hormone produced as a pro-peptide and cleaved into insulin and C-peptide. It promotes glucose uptake in muscle, glycogen synthesis, suppresses hepatic glucose output, and increases fatty acid uptake into fat cells. What insulin resistance means (Priority: 5/5): Insulin resistance is framed as an impaired ability of insulin to perform its normal functions, especially glucose uptake into muscle. The hosts note that resistance can manifest differently in muscle, liver, and fat. How insulin resistance is measured (Priority: 5/5): The episode contrasts research-grade methods like the euglycemic clamp and insulin suppression test with practical clinical tools. It emphasizes that fasting insulin/glucose and HOMA-IR are limited, while oral glucose tolerance testing is more informative. Clinical progression and early detection (Priority: 4/5): The discussion outlines a typical progression from normal metabolism to hyperinsulinemia, then elevated glucose, then fasting abnormalities, and finally diabetes. Early insulin resistance may appear as high postprandial insulin despite normal glucose. Metabolic syndrome and disease risk (Priority: 5/5): The hosts connect insulin resistance to metabolic syndrome and broader disease risk, including cardiovascular disease, cancer, and Alzheimer’s disease, underscoring its importance as a foundational health issue. Educational format and future episodes (Priority: 3/5): They suggest this deconstruction format could be used periodically for especially important and complex topics, helping listeners better understand high-value scientific discussions.

Key Arguments: Insulin is a pro-building hormone that drives glucose into muscle, supports glycogen storage, suppresses liver glucose release, and promotes fat storage in adipose tissue. Insulin resistance is best understood as impaired insulin action, not just elevated glucose or insulin values. Muscle insulin resistance is central because muscle is the major site of insulin-stimulated glucose disposal. Fasting glucose and fasting insulin are late markers and are not ideal standalone tests for early insulin resistance. HOMA-IR is a simple formula but is considered only marginally more useful than fasting insulin alone in this context. The oral glucose tolerance test is the best practical clinical tool discussed for assessing insulin resistance because it reveals both glucose and insulin responses over time. Early insulin resistance often shows up as disproportionately high post-meal insulin with normal glucose, before fasting abnormalities appear. Insulin resistance is not just about diabetes; it is linked to a broad spectrum of metabolic disease risk, including cardiovascular disease, cancer, and Alzheimer’s disease. Because insulin resistance is so prevalent and consequential, understanding it is essential for health optimization and disease prevention.

Data Points: Estimated prevalence of insulin resistance/metabolic dysregulation: about 88% - Peter Atiyah states that roughly 88% of people harbor some amount of insulin resistance or broader metabolic dysregulation. Insulin level during euglycemic clamp: 100 micro units per milliliter - Described as the fixed, high insulin concentration maintained during the clamp test. Oral glucose load: 75 grams of glucose - Standardized glucola drink used in the oral glucose tolerance test. OGTT sampling interval: every 30 minutes for 2 hours - Blood is drawn repeatedly after glucose ingestion to track glucose and insulin curves. HOMA-IR formula denominator: 405 - Fasting insulin times fasting glucose divided by 405 in common U.S. units. Typical fasting insulin comparison: 100 micro units/mL is about 10x higher than a desirable fasting insulin level - Used to contextualize the clamp’s insulin infusion level. Duration of insulin resistance study experience: 35 years - Peter references Gerald Shulman’s decades of work studying insulin resistance.

Pivotal Quotes: "you simply can't be healthy if you're insulin resistant" — Peter Atiyah: Peter frames insulin resistance as a foundational barrier to health and the reason this topic deserves deep attention. "about 88% of people harbor some amount of insulin resistance or metabolic dysregulation" — Peter Atiyah: Used to emphasize how common and underappreciated the problem is. "the best thing you can do clinically to ascend insulin resistance" — Peter Atiyah: Peter is referring to the oral glucose tolerance test as the most useful practical assessment tool.

Implications: Listeners should view insulin resistance as an early, central, and often silent driver of disease. Clinically, post-meal testing matters more than fasting labs alone, and understanding these mechanisms can guide prevention before diabetes develops.